Anti-EGFR therapy appears to be a potential treatment option for squamous cell anal carcinoma (SCAC). KRAS mutation is a rare event in SCAC, indicating the absence of the principal mechanism of resistance to this type of therapy. However, no information is available from the literature regarding the status of BRAF or PIK3CA in this cancer type. We analysed KRAS, BRAF and PIK3CA status in SCAC patients in relation to the clinical-pathological characteristics of patients and to the presence of the human papilloma virus (HPV). One hundred and three patients were treated with the Nigro scheme for anal cancer from March 2001 to August 2012. Fifty patients were considered for the study as there was insufficient paraffinembedded tumour tissue to perform molecular analysis the remaining 53. DNA was extracted from paraffin-embedded sections. KRAS, BRAF and PIK3CA gene status and HPV genotype were evaluated by pyrosequencing. KRAS and BRAF genes were wild-type in all cases. Conversely, PIK3CA gene was found to be mutated in 11 (22%) cases. In particular, 8 mutations occurred in exon 9 and 3 in exon 20 of the PIK3CA gene. These findings suggest that SCAC could potentially respond to an anti-EGFR drug. PIK3CA mutation may be involved in the process of carcinogenesis in some cases of SCAC. © 2014 Casadei Gardini et al.

KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC) / Casadei Gardini, Andrea; Capelli, Laura; Ulivi, Paola; Giannini, Massimo; Freier, Eva; Tamberi, Stefano; Scarpi, Emanuela; Passardi, Alassandro; Zoli, Wainer; Ragazzini, Angela; Amadori, Dino; Frassinet, Giovanni Luca. - In: PLOS ONE. - ISSN 1932-6203. - 9:(2014), pp. 1-6. [10.1371/journal.pone.0092071]

KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC)

Casadei Gardini, Andrea
;
Giannini, Massimo;Tamberi, Stefano;
2014

Abstract

Anti-EGFR therapy appears to be a potential treatment option for squamous cell anal carcinoma (SCAC). KRAS mutation is a rare event in SCAC, indicating the absence of the principal mechanism of resistance to this type of therapy. However, no information is available from the literature regarding the status of BRAF or PIK3CA in this cancer type. We analysed KRAS, BRAF and PIK3CA status in SCAC patients in relation to the clinical-pathological characteristics of patients and to the presence of the human papilloma virus (HPV). One hundred and three patients were treated with the Nigro scheme for anal cancer from March 2001 to August 2012. Fifty patients were considered for the study as there was insufficient paraffinembedded tumour tissue to perform molecular analysis the remaining 53. DNA was extracted from paraffin-embedded sections. KRAS, BRAF and PIK3CA gene status and HPV genotype were evaluated by pyrosequencing. KRAS and BRAF genes were wild-type in all cases. Conversely, PIK3CA gene was found to be mutated in 11 (22%) cases. In particular, 8 mutations occurred in exon 9 and 3 in exon 20 of the PIK3CA gene. These findings suggest that SCAC could potentially respond to an anti-EGFR drug. PIK3CA mutation may be involved in the process of carcinogenesis in some cases of SCAC. © 2014 Casadei Gardini et al.
2014
9
1
6
KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC) / Casadei Gardini, Andrea; Capelli, Laura; Ulivi, Paola; Giannini, Massimo; Freier, Eva; Tamberi, Stefano; Scarpi, Emanuela; Passardi, Alassandro; Zoli, Wainer; Ragazzini, Angela; Amadori, Dino; Frassinet, Giovanni Luca. - In: PLOS ONE. - ISSN 1932-6203. - 9:(2014), pp. 1-6. [10.1371/journal.pone.0092071]
Casadei Gardini, Andrea; Capelli, Laura; Ulivi, Paola; Giannini, Massimo; Freier, Eva; Tamberi, Stefano; Scarpi, Emanuela; Passardi, Alassandro; Zoli, Wainer; Ragazzini, Angela; Amadori, Dino; Frassinet, Giovanni Luca
File in questo prodotto:
File Dimensione Formato  
KRAS, BRAF and PIK3CA Status in Squamous Cell Anal Carcinoma (SCAC).pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 269.25 kB
Formato Adobe PDF
269.25 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1177509
Citazioni
  • ???jsp.display-item.citation.pmc??? 19
  • Scopus 44
  • ???jsp.display-item.citation.isi??? 37
social impact